Provided by Tiger Trade Technology Pte. Ltd.

Madrigal Pharmaceuticals

516.74
-2.3500-0.45%
Volume:179.83K
Turnover:93.50M
Market Cap:11.91B
PE:-36.35
High:530.67
Open:520.09
Low:514.91
Close:519.09
52wk High:615.00
52wk Low:393.61
Shares:23.06M
Float Shares:13.73M
Volume Ratio:0.65
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.2164
EPS(LYR):-12.8501
ROE:-53.31%
ROA:-17.84%
PB:22.75
PE(LYR):-40.21

Loading ...

Company Profile

Company Name:
Madrigal Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
915
Office Location:
1001 Conshohocken State Road,Suite 2-350,West Conshohocken,Pennsylvania,United States
Zip Code:
19428
Fax:
- -
Introduction:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

Directors

Name
Position
Bill Sibold
President and Chief Executive Officer and Director
Julian C. Baker
Independent Chairman of the Board and Independent Director
Jacqualyn A. Fouse
Independent Director
James Daly
Independent Director
Kenneth M. Bate
Independent Director
Paul A. Friedman
Independent Director
Raymond Cheong
Independent Director
Richard S. Levy
Independent Director
Rebecca Taub
Director

Shareholders

Name
Position
Bill Sibold
President and Chief Executive Officer and Director
Mardi Dier
Executive Vice President and Chief Financial Officer
Rita Thakkar
Senior Vice President and Chief Accounting Officer
Carole Huntsman
Executive Vice President and Chief Commercial Officer
David Soergel
Executive Vice President and Chief Medical Officer
Shannon Kelley
Executive Vice President and Chief Legal Counsel